Preclinical studies in support of phase I/II clinical trials to treat GUCY2D-associated Leber congenital amaurosis

[1]  B. Wilhelm,et al.  Longitudinal Evaluation of Hyper-Reflective Foci in the Retina Following Subretinal Delivery of Adeno-Associated Virus in Non-Human Primates , 2021, Translational vision science & technology.

[2]  A. J. Roman,et al.  Safety and improved efficacy signals following gene therapy in childhood blindness caused by GUCY2D mutations , 2021, iScience.

[3]  S. Boye,et al.  Novel AAV44.9-Based Vectors Display Exceptional Characteristics for Retinal Gene Therapy. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Nikolas Pontikos,et al.  GUCY2D-Associated Leber Congenital Amaurosis: A Retrospective Natural History Study in Preparation for Trials of Novel Therapies , 2019, American journal of ophthalmology.

[5]  Seng H. Cheng,et al.  Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes , 2017, Molecular therapy. Methods & clinical development.

[6]  B. Wilhelm,et al.  AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Omar H. Butt,et al.  Postretinal Structure and Function in Severe Congenital Photoreceptor Blindness Caused by Mutations in the GUCY2D Gene , 2017, Investigative ophthalmology & visual science.

[8]  S. Boye,et al.  Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors , 2016, Journal of Virology.

[9]  Seng H. Cheng,et al.  Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral Vectors. , 2015, Human gene therapy methods.

[10]  J. Pang,et al.  Trans-Corneal Subretinal Injection in Mice and Its Effect on the Function and Morphology of the Retina , 2015, PloS one.

[11]  W. Hauswirth,et al.  Gene Therapy Fully Restores Vision to the All-Cone Nrl(-/-) Gucy2e(-/-) Mouse Model of Leber Congenital Amaurosis-1. , 2015, Human gene therapy.

[12]  J. Chiorini,et al.  Structural Insights into Adeno-Associated Virus Serotype 5 , 2013, Journal of Virology.

[13]  S. Wadsworth,et al.  Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production. , 2013, Human gene therapy methods.

[14]  W. Hauswirth,et al.  AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. , 2013, Human gene therapy.

[15]  Paul D. Gamlin,et al.  The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. , 2012, Human gene therapy.

[16]  W. Hauswirth,et al.  Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. , 2011, Investigative ophthalmology & visual science.

[17]  W. Hauswirth,et al.  Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines , 2011, Molecular vision.

[18]  W. Hauswirth,et al.  Functional and Behavioral Restoration of Vision by Gene Therapy in the Guanylate Cyclase-1 (GC1) Knockout Mouse , 2010, PloS one.

[19]  M. Neider,et al.  Functional and anatomic consequences of subretinal dosing in the cynomolgus macaque. , 2010, Archives of ophthalmology.

[20]  R. Peluso,et al.  Manufacturing recombinant adeno-associated viral vectors from producer cell clones. , 2009, Human gene therapy.

[21]  W. Hauswirth,et al.  High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  B. Christian,et al.  Ocular Inflammation in Cynomolgus Macaques Following Intravenous Administration of a Human Monoclonal Antibody , 2009, International journal of toxicology.

[23]  A. J. Roman,et al.  Electroretinographic analyses of Rpe65-mutant rd12 mice: developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis. , 2007, Molecular vision.

[24]  A. J. Roman,et al.  Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. , 2006, Human gene therapy.

[25]  A. J. Roman,et al.  Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  W. Hauswirth,et al.  Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. , 2002, Methods.

[27]  K. Yau,et al.  Disruption of a Retinal Guanylyl Cyclase Gene Leads to Cone-Specific Dystrophy and Paradoxical Rod Behavior , 1999, The Journal of Neuroscience.

[28]  A. J. Roman,et al.  Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. , 2013, Human molecular genetics.